AG真人官方

STOCK TITAN

Jaguar Health Inc SEC Filings

JAGX NASDAQ

Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Reading Jaguar Health鈥檚 latest 10-K means wading through pages of FDA trial updates, rainforest sourcing details, and complex royalty tables鈥攅xactly the kind of biotech depth that can slow down even seasoned investors. If you鈥檝e ever searched, 鈥淗ow do I understand Jaguar Health SEC filings explained simply?鈥� you already know the challenge.

Stock Titan鈥檚 AI-powered analysis turns that complexity into clarity. We stream every Jaguar Health SEC filing the moment it hits EDGAR, then generate plain-language summaries that highlight what matters: Mytesi庐 sales trends inside the Jaguar Health annual report 10-K simplified, R&D spend spikes in each Jaguar Health quarterly earnings report 10-Q filing, and financing moves disclosed in an 8-K. Need fast answers? Ask in natural language鈥斺淲here can I see Jaguar Health executive stock transactions Form 4?鈥濃攁nd jump straight to the data.

Here鈥檚 what you can track in seconds:

  • AG真人官方-time alerts for Jaguar Health Form 4 insider transactions and option grants
  • Concise AI briefs of every 10-K, 10-Q, S-1, and Jaguar Health 8-K material events explained
  • Proxy statement insights covering Jaguar Health executive compensation and board matters
  • Side-by-side comparisons of pipeline disclosures across quarters

Whether you鈥檙e screening biotech catalysts, monitoring Jaguar Health insider trading Form 4 transactions, or preparing questions for the next earnings call, our platform saves hours and surfaces the signals hidden in regulatory prose. Discover understanding Jaguar Health SEC documents with AI鈥攁nd make better decisions, faster.

Rhea-AI Summary

iShares Trust 鈥� iShares GNMA Bond ETF (CIK: 0001100663) filed its monthly Form N-PORT report covering the period ended 30 April 2025.

Balance sheet: Total assets stand at $369.9 million against liabilities of $19.5 million, producing net assets of $350.4 million (liabilities 鈮� 5.3 % of assets).

Performance: The ETF recorded three consecutive positive months:

  • Feb 2025: +2.42 %
  • Mar 2025: +0.05 %
  • Apr 2025: +0.06 %

Cash flows: Share-transaction data show mixed demand. February produced a marginal net inflow of $10 k (sales $2.19 m vs redemptions $2.18 m), while April saw a $4.34 m net outflow. No transactions were reported for January.

Risk metrics (USD DV01 / DV100): A 1-bp parallel move shifts portfolio value by $74.5 k at the 10-year point; a 100-bp move would shift value by $7.45 m. Credit exposure is overwhelmingly investment grade with a modest 5-year CS01 of $169.6 k; there is no non-investment-grade exposure reported.

AG真人官方ised & unrealised results: February delivered realised gains of $369 k and unrealised gains of $6.85 m. March and April show combined realised/unrealised losses of roughly $2.46 m.

No borrowings, preferred shares, or off-balance-sheet leverage were reported. Securities-lending activity used non-cash collateral, but quantitative details were not provided. Highly Liquid Investment Minimum data were marked 鈥淣/A鈥�, and derivatives-specific VaR information was not included.

Take-away: The fund remains moderately sized, maintains investment-grade credit quality, and exhibits limited leverage. Performance has been mildly positive year-to-date, but April redemptions and recent unrealised losses warrant monitoring.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
current report
-
Filing
Rhea-AI Summary

Jaguar Health, Inc. (NASDAQ: JAGX) received SEC notice that its Form S-3 shelf registration statement (File No. 333-288202) became effective on June 27, 2025 at 4:00 p.m. ET. The effectiveness allows the company to register and potentially issue securities in the future without additional SEC review, streamlining capital-raising activities. No financial terms, transaction details, or earnings information were disclosed in the notice.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
other
-
Rhea-AI Summary

Jaguar Health, Inc. (Nasdaq: JAGX) has filed a Rule 424(b)(3) resale prospectus covering 507,390 shares of common stock that may be issued upon exercise of recently issued private-placement warrants. The registration allows the selling stockholders to freely resell: (i) 492,612 shares underlying common warrants priced at $5.84 per share and (ii) 14,778 shares underlying placement-agent warrants priced at $7.6125 per share. All warrants are immediately exercisable and expire on the earlier of (a) 24 months from the May 22 2025 issuance date, (b) a fundamental transaction, or (c) a liquidation event.

The company will receive no proceeds from secondary sales, but would collect up to roughly $3 million in gross proceeds if all warrants are exercised for cash. At the June 26 2025 closing price of $2.71, the warrants are out of the money, making near-term exercise unlikely and limiting immediate cash inflow. Nevertheless, the filing removes resale restrictions and may create an overhang on the stock once prices approach the exercise levels.

Investors should weigh the potential dilution of approximately 507 k shares against the modest, conditional capital infusion and review the company鈥檚 previously disclosed risk factors for additional context.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
prospectus
Rhea-AI Summary

Jaguar Health has filed a prospectus supplement (No. 5) to amend its At-The-Market (ATM) offering program. The key updates include:

Key Details:

  • Maximum offering reduced to $3,378,239 worth of common stock shares
  • Current stock price: $2.71 per share (as of June 26, 2025)
  • Trading symbol: JAGX on Nasdaq
  • Non-affiliate market value: approximately $19.0 million (1,463,644 shares at $12.98)

The company has become subject to Form S-3's General Instruction I.B.6 limitations as of March 31, 2025. They have already sold approximately $2.95 million worth of shares in the prior 12-month period. The ATM program is being conducted through Ladenburg Thalmann & Co. and Lucid Capital Markets as sales agents, with all other terms remaining unchanged from the original agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
prospectus
-
Rhea-AI Summary

Form 4 Filing: Insider Trading Activity for Jaguar Health (JAGX) reports significant changes in derivative securities holdings by Director Jonathan B. Siegel through JBS Healthcare Ventures LLC on June 24, 2025.

Key transactions include:

  • Disposition of original 6% convertible promissory note (9,000 shares at $5.555 conversion price, maturing 6/30/2025)
  • Acquisition of new 6% convertible promissory note (9,462 shares at $5.555 conversion price, maturing 1/30/2026)
  • Receipt of warrant to purchase 18,262 common shares at $2.70 exercise price, expiring 12/24/2026

The exchange was part of an issuer exchange offer, with the warrant serving as an inducement. The warrant becomes exercisable upon stockholder approval. All securities are held indirectly through JBS Healthcare Ventures LLC, where Siegel serves as sole member.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags
insider
-
Rhea-AI Summary

Form 4 snapshot: Jaguar Health, Inc. (JAGX) director John Micek reported a series of related transactions dated 06/24/2025 that modify his derivative exposure to company equity.

Key transactions

  • Exchange of 6% Convertible Note: Micek disposed of the original 6% note maturing 06/30/2025 that was convertible into 9,000 common shares. In its place he acquired a new 6% promissory note maturing 01/30/2026, convertible at the holder鈥檚 option into 9,462 common shares at a conversion price of $5.555 per share.
  • Inducement warrant: As consideration for the exchange, he received a warrant to purchase up to 18,262 common shares at an exercise price of $2.70. The warrant becomes exercisable once shareholder approval is obtained and will lapse on the earliest of (i) 18 months after issuance, (ii) the completion of a fundamental transaction, or (iii) a liquidation event.

Post-transaction holdings (derivatives only)

  • Convertible Note (new): 9,462 underlying shares
  • Warrant: 9,000 derivative securities beneficially owned (table value) with an aggregate right to purchase 18,262 shares

Implications for investors

  • The new note extends the debt maturity by seven months, modestly improving Jaguar鈥檚 near-term cash-flow pressure.
  • The combined instruments create potential dilution of up to 27,724 additional shares (9,462 from conversion + 18,262 from warrant) once fully exercised/converted.
  • The warrant strike price ($2.70) is significantly below the note conversion price ($5.555), suggesting a higher likelihood of exercise if market price exceeds $2.70 post-approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags
insider
Rhea-AI Summary

Director James J. Bochnowski of Jaguar Health (JAGX) reported significant changes in derivative securities holdings on June 24, 2025. The transactions involved the restructuring of convertible debt and issuance of new warrants:

  • Disposed of an existing 6% convertible promissory note (27,002 shares at $5.555 conversion price) maturing June 30, 2025
  • Acquired a new 6% convertible promissory note (28,388 shares at $5.555 conversion price) maturing January 30, 2026
  • Received a warrant to purchase 54,786 shares at $2.70 per share, exercisable upon stockholder approval and expiring December 24, 2026

All securities are held indirectly through the Bochnowski Family Trust, where Mr. Bochnowski serves as co-trustee with shared voting and investment control. The exchange was part of an issuer exchange offer, effectively extending the debt maturity by 7 months while providing additional warrant coverage as an inducement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags
insider
-
Rhea-AI Summary

Steven R. King, Chief of Sustainable Supply, Ethnobotanical Research and IP and Secretary of Jaguar Health (JAGX), reported significant changes in derivative securities holdings on June 24, 2025:

  • Disposed of an existing 6% convertible promissory note (Original Note) maturing 6/30/2025
  • Acquired a new 6% convertible promissory note (New Note) maturing 1/30/2026, convertible to 3,785 shares at $5.555 per share
  • Received a warrant as inducement for the exchange, allowing purchase of 7,304 shares at $2.70 per share

The warrant becomes exercisable upon stockholder approval and expires in 18 months (12/24/2026) or earlier upon fundamental transaction/liquidation events. This exchange effectively extends the maturity of King's convertible note position while providing additional equity exposure through the warrant.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags
insider
-
Rhea-AI Summary

Jaguar Health's Chief Scientific Officer Pravin R. Chaturvedi reported significant changes in derivative securities holdings on June 24, 2025. The transactions involved restructuring of convertible debt and issuance of new warrants:

  • Disposed of original 6% convertible promissory note (3,600 shares at $5.555 conversion price) maturing June 30, 2025
  • Acquired new 6% convertible promissory note (3,785 shares at $5.555 conversion price) maturing January 30, 2026
  • Received warrant to purchase 7,304 shares at $2.70 exercise price as inducement for exchange

The warrant is exercisable upon stockholder approval and expires the earlier of: 18 months from issuance, fundamental transaction completion, or liquidation event. Both notes have principal value of $20,000. This exchange effectively extends the debt maturity while providing additional equity upside through warrants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags
insider
Rhea-AI Summary

Jonathan S. Wolin, Chief of Staff, Chief Compliance Officer and General Counsel of Jaguar Health (JAGX), reported significant changes in derivative securities holdings on June 24, 2025:

  • Disposed of an existing 6% convertible promissory note due 6/30/2025 (Original Note) in exchange for a new note through an issuer exchange offer
  • Received a new 6% convertible promissory note maturing 1/30/2026, convertible into 9,462 shares of common stock at $5.555 per share
  • As inducement, received a warrant to purchase 18,262 shares at $2.70 per share, exercisable upon stockholder approval and expiring after 18 months

This transaction represents a restructuring of the executive's convertible debt holdings, extending the maturity date by 7 months and providing additional equity exposure through warrants. The new note's conversion terms and warrant structure suggest potential upside participation in the company's future performance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.19%
Tags
insider

FAQ

What is the current stock price of Jaguar Health (JAGX)?

The current stock price of Jaguar Health (JAGX) is $2.63 as of July 10, 2025.

What is the market cap of Jaguar Health (JAGX)?

The market cap of Jaguar Health (JAGX) is approximately 3.4M.

What is Jaguar Health Inc's core business?

Jaguar Health Inc focuses on developing novel, plant-based prescription medicines for gastrointestinal distress in both humans and animals. The company leverages sustainable botanical sources to create non-opioid, anti-secretory therapies.

How does Jaguar Health generate its revenue?

The company generates revenue primarily through its human health segment, which includes the commercialization of therapies like Mytesi庐 for symptomatic relief of noninfectious diarrhea. Additionally, its animal health segment provides targeted treatments for companion and performance animals.

What makes Jaguar Health's products unique?

Jaguar Health develops therapies using sustainably harvested, rainforest-derived botanicals, ensuring ecological integrity and traditional medicinal value. Their products, such as crofelemer-based therapies, offer localized therapeutic effects that address multiple gastrointestinal disorders.

What are some of the company's key products?

Key products include Mytesi庐, a prescription drug for relieving chronic noninfectious diarrhea in adults with HIV/AIDS, and other candidates like Canalevia鈩� for canine diarrhea and Equilevia鈩� for equine gut health. These products exemplify their dual focus on human and animal health.

How does Jaguar Health incorporate sustainability into its operations?

Jaguar Health sources its active botanical ingredients from rainforest plants using sustainable harvesting practices and fair trade principles. This approach not only ensures high-quality, natural compounds but also supports indigenous communities and preserves ecological integrity.

Who are the target customers of Jaguar Health?

The company's target customers include patients suffering from chronic gastrointestinal disorders, both in human medicine and veterinary care. It also serves healthcare providers and veterinary professionals seeking natural and sustainable therapeutic solutions.

How does Jaguar Health differentiate itself from competitors?

Jaguar Health distinguishes itself through its commitment to sustainable, plant-based research, a diversified product portfolio across human and animal health, and a rigorous clinical approach backed by extensive scientific expertise. Its unique botanical sourcing and innovative formulations set it apart in the natural pharmaceuticals market.

What role does Napo Pharmaceuticals play in Jaguar Health's business?

Napo Pharmaceuticals, a wholly-owned subsidiary of Jaguar Health, is dedicated to developing and commercializing human prescription pharmaceuticals. It plays a crucial role in extending the company鈥檚 reach in addressing neglected gastrointestinal symptoms through advanced clinical research and product development.
Jaguar Health Inc

NASDAQ:JAGX

JAGX Rankings

JAGX Stock Data

3.40M
1.17M
14.81%
1.71%
5.81%
Biotechnology
Pharmaceutical Preparations
United States
SAN FRANCISCO